	US 12,145,917 B2
	Crystalline forms of a compound for treating or preventing gout or hyperuricemia
Shunqi Yan, Laguna Hills, CA (US); Litain Yeh, Laguna Hills, CA (US); Zheng Jane Li, Beijing (CN); and Ruiping Wang, Beijing (CN)
Assigned to ARTHROSI THERAPEUTICS, INC., San Diego, CA (US)
Appl. No. 17/311,249
Filed by Arthrosi Therapeutics, Inc., Laguna Hills, CA (US)
PCT Filed Dec. 5, 2019, PCT No. PCT/US2019/064784 § 371(c)(1), (2) Date Jun. 4, 2021, PCT Pub. No. WO2020/118113, PCT Pub. Date Jun. 11, 2020.
Prior Publication US 2022/0024889 A1, Jan. 27, 2022
Int. Cl. C07D 307/80 (2006.01); A61K 45/06 (2006.01)

CPC C07D 307/80 (2013.01) [A61K 45/06 (2013.01); C07B 2200/13 (2013.01)]

18 Claims

1. A crystalline form of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-d₄)methanone, wherein the crystalline form of (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-d₄)methanone is Form 3 having at least one of the following properties:

(a) an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 6.8° 2-Theta, 13.6° 2-Theta, 14.6° 2-Theta, 21.2° 2-Theta, 24.2° 2-Theta, 24.7° 2-Theta, 26.7° 2-Theta, and 27.5° 2-Theta;

(b) a DSC thermogram with an endotherm having an onset at 147° C.; or